Xtx Topco LTD Karyopharm Therapeutics Inc. Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 25,905 shares of KPTI stock, worth $16,579. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,905

Previous 140,576 81.57%

Holding current value

$16,579

Previous $122,000 82.79%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.7 - $1.06 $80,269 - $121,551	-114,671 Reduced 81.57%	25,905 $21,000
Q2 2024 Aug 12, 2024	SELL	$0.87 - $1.58 $88,970 - $161,578	-102,265 Reduced 42.11%	140,576 $122,000
Q1 2024 May 13, 2024	BUY	$0.72 - $1.66 $139,477 - $321,573	193,719 Added 394.36%	242,841 $366,000
Q4 2023 Feb 13, 2024	SELL	$0.68 - $1.31 $177,441 - $341,835	-260,943 Reduced 84.16%	49,122 $42,000
Q3 2023 Nov 13, 2023	SELL	$1.14 - $1.81 $84,112 - $133,547	-73,783 Reduced 19.22%	310,065 $415,000
Q2 2023 Aug 14, 2023	BUY	$1.79 - $4.59 $687,087 - $1.76 Million	383,848 New	383,848 $687,000
Q4 2022 Feb 14, 2023	BUY	$2.48 - $5.93 $223,884 - $535,336	90,276 Added 222.68%	130,817 $444,000
Q3 2022 Nov 14, 2022	SELL	$4.08 - $5.82 $45,145 - $64,398	-11,065 Reduced 21.44%	40,541 $221,000
Q2 2022 Aug 15, 2022	BUY	$4.15 - $8.37 $154,284 - $311,171	37,177 Added 257.65%	51,606 $233,000
Q1 2022 May 13, 2022	BUY	$5.91 - $14.38 $8,143 - $19,815	1,378 Added 10.56%	14,429 $106,000
Q4 2021 Feb 11, 2022	SELL	$5.21 - $8.61 $16,781 - $27,732	-3,221 Reduced 19.79%	13,051 $84,000
Q3 2021 Nov 12, 2021	BUY	$4.45 - $10.63 $72,410 - $172,971	16,272 New	16,272 $95,000

Others Institutions Holding KPTI

# of Institutions

Shares Held

57.6M

Call Options Held

258K

Put Options Held

81.2K

View Full List

About Karyopharm Therapeutics Inc.

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $51.1M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

More about KPTI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account